In the middle of the generalized default in agro, Rizobacter Paga On for more than US $12 million

In the middle of the generalized default in agro, Rizobacter Paga On for more than US  million

Rizobacter, the biological supplies company that is part of the Bioceres group, once again takes off from the situation that other great firms from the sector such as Los Grobo, Agrofina and Surcos arewith Millionaire default and even call for creditors. In this way, the company reported that next February 10 will make the eighth payment of your series of negotiable obligations (ON) Series VIII, with a total disbursement of little more than US $ 12.3 million.

Payment is divided into two kinds of obligations. In the case of the Class athe company will pay US $ 12.2 million in capitalwhich represents a 75% amortization of the original amount. To this are added U $ 45,983 in interest.

On the other hand, the Class B You will not have capital amortization in this payment, but a disbursement of U $50,326 in interest. In total, the company will pay $ s12.39 millionwhich will be accredited in the sub -accounts of the holders of the negotiable obligations through Securities box.

With this movement, the company demonstrates its commitment to investors and reinforces its position in the financial market, where in repeated opportunities it resorted to financing. One of the keys to this company is that behind the giant and powerful bioceres group that even trades its actions in Nasdaq with the Biox Ticker.

Rizobacter is dedicated to the research, development, production and marketing of microbiological agro -support for crop protection and nutrition, including fertilizers, inoculants and adjuvants. The company has a trajectory of more than 35 years in the Argentine market, a diversified portfolio of products, operations in Argentina, Brazil, Uruguay, Paraguay, Bolivia, the United States, South Africa, Colombia and France, and sales in more than 40 countries .

As explained in the sector, although Rizobacter operates in a context of high competition, the quality and differentiation of its products allows the company to maintain a high market positioning, which derives in the possibility of setting prices above standard products.

Rizobacter also has a solid competitive position in the markets in which he operates, both in the local and international market. The company is a leader in the soy inoculants category, having 23% world market share.

Consulted by Scopein the company they pointed out that despite the complex context that crosses agriculture in Argentina, 2024 It has been an acceptable year for biological products. “It is important to keep in mind that in addition to Argentina, where complex situations have been had, especially for chemicals, We operate in Brazil, Europe and the United States with a diversified portfolio and that atomizes the operational risk”They said in the firm.

Source: Ambito

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest Posts